Partnerships

Improving your path to and through the clinic with a regulatory and commercially proven expression platform. Licensing opportunities available for preclinical and clinically developed therapeutics.

Are you seeking to improve the production, economics, and overall derisking the development of your therapeutics?

We ask you to leverage our PET platform capabilities with us, that includes rapid candidate selection, high success rates for expressing challenging molecules, and a reduced time-to-clinic for a wide range of complex modalities.  With more than 60 world-wide collaborations with pharmaceutical organizations over the last twenty years, our deep institutional knowledge and unmatched capabilities bring significant value to your product development program. Consider Pelican your experienced partner in expression optimization and the CMC arm for your organization as you prepare for entering the clinic and beyond.

In pursuit of our vision, we have also created a portfolio of therapeutics, produced by our patented Pelican Expression Technology™ platform, many of which include biosimilars and biobetters.  Many of these candidates have been developed through Phase I clinical trials and are available for license.

Please contact [email protected] to request more information to engage Pelican as your trusted drug development partner.

Our Collaborations

Pre-clinical

Phase 1

Phase 2

Phase 3

Reg. Filing

Commercial

Partner

PF708

Teriparatide Injection (PF708, Bonsity™)

Phase: Reg. Filing

Partner: Alvogen & Kangchen

PF708 - Teriparatide – Osteoporosis

PF743

Rylaze™ (JZP-458, Recombinant Erwinia Asparaginase)

Phase: Commercial

Partner: Jazz Pharmaceuticals

PF743 (JZP-458) - Recombinant Erwinia asparaginase

PF745(JZP-341)

Long-acting Recombinant Erwinia Asparaginase

Phase: Preclinical

Partner: Jazz Pharmaceuticals

PF745(JZP-341) - Recombinant long-acting Erwinia asparaginase

PF690

Arcellx CART – SparX

PF690 - Arcellx CART - sparX

CRM197

Carrier Protein

Phase: Phase 3

Phase: Add’l Programs – Pre-clinical

Partner: Merck

CRM197 - Carrier Protein

CRM197

Carrier Protein

Phase: Pneumosil – Reg. Filing

Phase: Meningococcal Vaccine – Commercial

Phase: Add’l Programs – Commercial

Partner: Serum Institute of India PVT. LTD.

CRM197 - Carrier Protein

CRM197

Carrier Protein

Phase: Phase 2

Partner: Various undisclosed partnerships

CRM197 - Carrier Protein

Various undisclosed partnerships

PCV-15

V114

PCV-15 V114

Pneumosil

10-Valent Pneumococcal Vaccine

Pneumosil 10-valent Pneumococcal vaccine

Pentavalent Meningococcal Conjugate Vaccine

Pentavalent Meningococcal Conjugate Vaccine

PF810

Recombinant Peptide

Phase: Pre-clinical

Partner: Pfenex Biopharmaceuticals

PF810 - Recombinant Peptide

PF753

Arcellx ARC-T – sparX

Phase: Pre-clinical

Partner: Arcellx

PF753 - Arcellx CART - sparX

PF754

Arcellx ARC-T – sparX

Phase: Pre-clinical

Partner: Arcellx

PF754 - Arcellx CART - sparX

PF582

Arcellx ARC-T – SparX

PF582 - Arcellx CART - sparX

Select Partners

Pelican has granted Alvogen the exclusive rights to commercialize and manufacture Pelican’s lead drug candidate, Teriparatide Injection (previously referred to as PF708 and Bonsity), which is being developed as a therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®/Forsteo®, in the United States, the European Union, certain countries in the Middle East and North Africa and the Rest of World territories outside of the countries licensed to Kangchen including, Hong Kong, Mainland China, Malaysia, Singapore and Thailand. Teriparatide Injection (PF708) was developed via the 505(b)(2) regulatory pathway in the United States, and was FDA approved on October 4, 2019 and commercially launched in the US on June 11, 2020. Approval and launch followed in the EU and is ongoing in additional territories.

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. With commercial footprint in over 35 countries, Alvogen’s key regions include the U.S. and emerging markets in the CEE and APAC regions.

Pelican has granted Beijing Kangchen Biological Technology Co. Ltd. (Kangchen), a joint venture between Beijing Konruns Pharmaceutical Co. Ltd. and NT Pharma International Company Limited the exclusive rights to commercialize Pelican’s lead drug candidate, Teriparatide Injection (PF708) which is being developed as a therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®/Forsteo®, in Hong Kong, Mainland China, Malaysia, Singapore and Thailand.

Pelican granted Jazz Pharmaceuticals (“Jazz”) worldwide rights to develop and commercialize multiple early stage hematology product candidates including a recombinant Erwinia asparaginase, PF743 (JZP-458), a potential treatment option for patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginase products and PF745 (JZP-341), a half-life extended recombinant Erwinia asparaginase. The agreement also includes an option for Jazz to negotiate a license for a recombinant pegaspargase product candidate with Pelican.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development and is focused on transforming biopharmaceutical discoveries into novel medicines.

Merck & Co., Inc. currently has a license agreement for the use of Pelican Expression Technology™ to produce the carrier protein CRM197 for use in conjugate vaccines they are developing.  Merck is currently utilizing Pelican expressed CRM197 in their 15-valent Pneumococcal vaccine, V114, plus additional vaccine development programs.

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.

Serum Institute of India Private Limited (SIIPL) currently has a license agreement for the use of Pelican Expression Technology™ to produce the carrier protein CRM197 for use in conjugate vaccines they are developing.  SIIPL is currently utilizing Pelican expressed CRM197 in Pneumosil®, a 10-valent Pneumococcal vaccine, that achieved WHO Prequalification in December 2019. SIIPL is also developing a thermostable Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) that is currently being evaluated in a Phase 3 clinical study plus additional vaccine development programs. In addition, SIIPL is Pelican’s exclusive supplier of pre-clinical grade and cGMP grade CRM197 which Pelican sells to vaccine developers globally, see www.CRM197.com for more information.

Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines manufactured by SIIPL are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.